

Anthony S Wierzbicki

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8500777/anthony-s-wierzbicki-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

342
papers

7,802
citations

44
h-index

75
g-index

392
ext. papers

8,930
ext. citations

6
avg, IF

6.22
L-index

#	Paper	IF	Citations
342	Triglycerides and cardiovascular disease. <i>Current Opinion in Cardiology</i> , 2021 , 36, 469-477	2.1	2
341	Impact of Therapeutic Inertia on Long-Term Blood Pressure Control: A Monte Carlo Simulation Study. <i>Hypertension</i> , 2021 , 77, 1350-1359	8.5	1
340	Screening for patients with Gaucher's disease using routine pathology results: PATHFINDER (ferritin, alkaline phosphatase, platelets) study. <i>International Journal of Clinical Practice</i> , 2021 , 75, e14422 ^{2.9}		
339	Investigating raised creatine kinase. <i>BMJ, The</i> , 2021 , 373, n1486	5.9	
338	Options for the diagnosis of high blood pressure in primary care: a systematic review and economic model. <i>Journal of Human Hypertension</i> , 2021 , 35, 455-461	2.6	3
337	Identification of patients with Fabry disease using routine pathology results: PATHFINDER (eGFR) study. <i>International Journal of Clinical Practice</i> , 2021 , 75, e13672	2.9	1
336	Cost-Effectiveness of Initiating Pharmacological Treatment in Stage One Hypertension Based on 10-Year Cardiovascular Disease Risk: A Markov Modeling Study. <i>Hypertension</i> , 2021 , 77, 682-691	8.5	4
335	Elevated Lipoprotein(a): Background, Current Insights and Future Potential Therapies. <i>Vascular Health and Risk Management</i> , 2021 , 17, 527-542	4.4	1
334	Reorganizing the treatment of cardiovascular disease in response to coronavirus disease 2019; time for the poly-pill?. <i>Current Opinion in Cardiology</i> , 2020 , 35, 428-433	2.1	5
333	Ten tips for promoting your research. <i>Cardiovascular Endocrinology and Metabolism</i> , 2020 , 9, 30-35	2.5	78
332	Managing cardiovascular disease risk in hypertension. <i>Lancet, The</i> , 2020 , 395, 869-870	4.0	3
331	Low cholesterol syndrome and drug development. <i>Current Opinion in Cardiology</i> , 2020 , 35, 423-427	2.1	0
330	The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease. <i>Therapeutic Advances in Chronic Disease</i> , 2020 , 11, 2040622320924569	4.9	1
329	Cardiovascular prevention: Frontiers in lipid guidelines. <i>Clinical Medicine</i> , 2020 , 20, 36-42	1.9	3
328	Volanesorsen in the Treatment of Familial Chylomicronemia Syndrome or Hypertriglyceridaemia: Design, Development and Place in Therapy. <i>Drug Design, Development and Therapy</i> , 2020 , 14, 2623-2636 ^{4.4}	4.4	16
327	Phenomics, Not Genomics, for Cardiovascular Risk Assessment. <i>Circulation</i> , 2020 , 142, 821-823	16.7	
326	Primum non nocere: Demand management in pathology and preventing harm. <i>International Journal of Clinical Practice</i> , 2019 , 73, e13311	2.9	0

325	An audit of research productivity in clinical biochemistry revisited. <i>JRSM Open</i> , 2019 , 10, 2054270419844181		
324	Hypertension in adults: summary of updated NICE guidance. <i>BMJ, The</i> , 2019 , 367, l5310	5.9	32
323	Genetic risk scores in lipid disorders. <i>Current Opinion in Cardiology</i> , 2019 , 34, 406-412	2.1	3
322	Identification of patients with Pompe disease using routine pathology results: PATHFINDER (creatin kinase) study. <i>Journal of Clinical Pathology</i> , 2019 , 72, 805-809	3.9	2
321	Bile acid metabolism is altered in those with insulin resistance after gestational diabetes mellitus. <i>Clinical Biochemistry</i> , 2019 , 64, 12-17	3.5	10
320	Identification of rare diseases by screening a population selected on the basis of routine pathology results-the PATHFINDER project: lysosomal acid lipase/cholesteryl ester storage disease substudy. <i>Journal of Clinical Pathology</i> , 2018 , 71, 608-613	3.9	6
319	Is Lp(a) ready for prime time use in the clinic? A pros-and-cons debate. <i>Atherosclerosis</i> , 2018 , 274, 16-22	3.1	23
318	Chylomicronemia Syndrome 2018 , 742-759		
317	An update on trials of novel lipid-lowering drugs. <i>Current Opinion in Cardiology</i> , 2018 , 33, 416-422	2.1	3
316	Suboptimal rise in awakening-induced cortisol is an accurate marker of cortisol insufficiency in patients with normal renal function (eGFR >60 mL/min). <i>Annals of Clinical Biochemistry</i> , 2018 , 55, 496-499 ²⁻²		
315	Demand management of weekend haematology and clinical biochemistry requests. <i>International Journal of Clinical Practice</i> , 2018 , 73, e13297	2.9	2
314	Chronic heart failure in adults: summary of updated NICE guidance. <i>BMJ, The</i> , 2018 , 362, k3646	5.9	14
313	Review of referral criteria to lipid clinics and outcomes of treatment in four UK centres. <i>International Journal of Clinical Practice</i> , 2018 , 72, e13242	2.9	1
312	Further options for treating lipids in people with diabetes: targeting LDL-cholesterol and beyond. <i>Diabetic Medicine</i> , 2018 , 35, 1173	3.5	2
311	Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome. <i>Expert Review of Clinical Pharmacology</i> , 2018 , 11, 589-598	3.8	22
310	Radiotherapy, chemotherapy and atherosclerosis. <i>Current Opinion in Cardiology</i> , 2017 , 32, 441-447	2.1	13
309	Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2017 , 35, 537-547 ⁴⁻⁴	4.4	15
308	The challenges of proprotein convertase subtilisin-kexin-9 inhibitors for lipid guidelines and models of care. <i>Current Opinion in Lipidology</i> , 2017 , 28, 470-476	4.4	1

307	Pro-protein subtilisin kexin-9 (PCSK9) inhibition in practice: lipid clinic experience in 2 contrasting UK centres. <i>International Journal of Clinical Practice</i> , 2017 , 71, e13032	2.9	25
306	The impact of lipoprotein lipase deficiency on health-related quality of life: a detailed, structured, qualitative study. <i>Orphanet Journal of Rare Diseases</i> , 2017 , 12, 156	4.2	5
305	The Challenges of a Successful Pregnancy in a Patient with Adult Refsum's Disease due to Phytanoyl-CoA Hydroxylase Deficiency. <i>JIMD Reports</i> , 2017 , 33, 49-53	1.9	3
304	Familial hypercholesterolaemia. <i>Nature Reviews Disease Primers</i> , 2017 , 3, 17093	51.1	190
303	Assessment of a semi-quantitative screening method for diagnosis of ethylene glycol poisoning. <i>Annals of Clinical Biochemistry</i> , 2017 , 54, 501-503	2.2	1
302	Statins, Muscle Disease and Mitochondria. <i>Journal of Clinical Medicine</i> , 2017 , 6,	5.1	45
301	Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2016 , 35, 537	4.4	4
300	Anti-sense oligonucleotide therapies for the treatment of hyperlipidaemia. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 1125-34	5.4	19
299	Safety of long-term restrictive diets for peroxisomal disorders: vitamin and trace element status of patients treated for Adult Refsum Disease. <i>International Journal of Clinical Practice</i> , 2016 , 70, 229-35	2.9	5
298	Nonfasting Sample for the Determination of Routine Lipid Profile: Is It an Idea Whose Time Has Come?. <i>Clinical Chemistry</i> , 2016 , 62, 428-35	5.5	15
297	Familial Hypercholesterolaemia in the Era of Genetic Testing. <i>Current Cardiology Reports</i> , 2016 , 18, 42	4.2	5
296	Statin myopathy: over-rated and under-treated?. <i>Current Opinion in Cardiology</i> , 2016 , 31, 417-25	2.1	6
295	Diabetic Dyslipidemia and Risk of Cardiovascular Disease 2016 , 643-652		
294	Drugs for hypercholesterolaemia - from statins to pro-protein convertase subtilisin kexin 9 (PCSK9) inhibition. <i>Clinical Medicine</i> , 2016 , 16, 353-7	1.9	8
293	Erectile dysfunction and coronary heart disease. <i>Current Opinion in Cardiology</i> , 2015 , 30, 416-21	2.1	26
292	Improving the odds: ezetimibe and cardiovascular disease. <i>International Journal of Clinical Practice</i> , 2015 , 69, 390-5	2.9	2
291	Bariatric surgery in obese older people. <i>Cardiovascular Endocrinology</i> , 2015 , 4, 60-66		3
290	Pro-protein convertase subtilisin/kexin 9 concentrations correlate with coronary artery disease atheroma burden in a Pakistani cohort with chronic chest pain. <i>International Journal of Clinical Practice</i> , 2015 , 69, 738-42	2.9	8

289	The hinterland of familial hypercholesterolaemia: what do we not know?. <i>Current Opinion in Lipidology</i> , 2015 , 26, 475-83	4.4	4
288	Prioritizing health outcomes in a limited world: writing lipid guidelines. <i>Current Opinion in Lipidology</i> , 2015 , 26, 188-94	4.4	1
287	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. <i>European Journal of Preventive Cardiology</i> , 2015 , 22, 849-54	3.9	35
286	The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2015 , 132, 2167-92	16.7	377
285	Evaluating quality and its determinants in lipid control for secondary prevention of heart disease and stroke in primary care: a study in an inner London Borough. <i>BMJ Open</i> , 2015 , 5, e008678	3	4
284	Vitamin K and other markers of micronutrient status in morbidly obese patients before bariatric surgery. <i>International Journal of Clinical Practice</i> , 2015 , 69, 638-42	2.9	15
283	Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. <i>BMJ, The</i> , 2014 , 349, g4356	5.9	177
282	The ebbs and flows in the development of cholesterol-lowering drugs: prospects for the future. <i>Clinical Pharmacology and Therapeutics</i> , 2014 , 96, 64-73	6.1	12
281	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. <i>International Journal of Cardiology</i> , 2014 , 171, 309-25	3.2	251
280	Angiographic coronary artery disease and high-sensitivity troponin-T in a native Pakistani cohort presenting with chronic chest pain. <i>International Journal of Clinical Practice</i> , 2014 , 68, 1473-7	2.9	
279	Interrupting the natural history of diabetes mellitus: lifestyle, pharmacological and surgical strategies targeting disease progression. <i>Current Vascular Pharmacology</i> , 2014 , 12, 155-67	3.3	6
278	Fibrates and niacin: is there a place for them in clinical practice?. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 2673-80	4	8
277	Dyslipidaemia: what's around the corner?. <i>Clinical Medicine</i> , 2014 , 14 Suppl 6, s41-4	1.9	3
276	Statin-fibrate combination therapy is safe and effective in normalizing lipid profile and in keeping cardiovascular event rates low. <i>Current Medical Research and Opinion</i> , 2014 , 30, 57-8	2.5	2
275	Lipid-lowering drug therapies and chronic obstructive pulmonary disease: lung failure or just heart failure?. <i>International Journal of Clinical Practice</i> , 2014 , 68, 144-51	2.9	1
274	Should we expand the concept of coronary heart disease equivalents?. <i>Current Opinion in Cardiology</i> , 2014 , 29, 389-95	2.1	26
273	Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. <i>Journal of Clinical Lipidology</i> , 2014 , 8, 148-72	4.9	79
272	Dyslipidaemia related to insulin resistance and cardiovascular disease in South Asian and West African populations. <i>Current Pharmaceutical Design</i> , 2014 , 20, 6270-5	3.3	7

271	Lipid-lowering agents. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2013 , 18, 401-11	2.6	23
270	U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. <i>British Journal of Dermatology</i> , 2013 , 168, 192-200	4	64
269	Screening for chronic comorbid diseases in people with HIV: the need for a strategic approach. <i>HIV Medicine</i> , 2013 , 14 Suppl 1, 1-11	2.7	22
268	The need for combination drug therapies in patients with complex dyslipidemia. <i>Current Cardiology Reports</i> , 2013 , 15, 391	4.2	7
267	Effectiveness of alternative strategies to define index case phenotypes to aid genetic diagnosis of familial hypercholesterolaemia. <i>Heart</i> , 2013 , 99, 175-80	5.1	30
266	Epicardial fat and vascular risk: a narrative review. <i>Current Opinion in Cardiology</i> , 2013 , 28, 458-63	2.1	53
265	CDKN2B expression in adipose tissue of familial combined hyperlipidemia patients. <i>Journal of Lipid Research</i> , 2013 , 54, 3491-505	6.3	21
264	New therapies to reduce low-density lipoprotein cholesterol. <i>Current Opinion in Cardiology</i> , 2013 , 28, 452-7	2.1	19
263	Novel therapies for dyslipidemia 2013 , 58-69		
262	Homozygous familial hypercholesterolemia. <i>Clinical Lipidology</i> , 2013 , 8, 407-409		1
261	A cross-sectional randomised study of fracture risk in people with HIV infection in the probono 1 study. <i>PLoS ONE</i> , 2013 , 8, e78048	3.7	21
260	New directions in cardiovascular risk assessment: the role of secondary risk stratification markers. <i>International Journal of Clinical Practice</i> , 2012 , 66, 622-30	2.9	16
259	Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study. <i>Current Medical Research and Opinion</i> , 2012 , 28, 371-8	2.5	37
258	Inhibition of pro-protein convertase subtilisin kexin 9 [corrected] (PCSK-9) as a treatment for hyperlipidaemia. <i>Expert Opinion on Investigational Drugs</i> , 2012 , 21, 667-76	5.9	30
257	Lipid Management 2012 , 449-460		
256	The origin, global distribution, and functional impact of the human 8p23 inversion polymorphism. <i>Genome Research</i> , 2012 , 22, 1144-53	9.7	48
255	New lipid-lowering drugs: an update. <i>International Journal of Clinical Practice</i> , 2012 , 66, 270-80	2.9	48
254	The effect of a 12-week course of omega-3 polyunsaturated fatty acids on lipid parameters in hypertriglyceridemic adult HIV-infected patients undergoing HAART: a randomized, placebo-controlled pilot trial. <i>Clinical Therapeutics</i> , 2012 , 34, 67-76	3.5	23

253	Triglycerides: a case for treatment?. <i>Current Opinion in Cardiology</i> , 2012 , 27, 398-404	2.1	24
252	Statins and noncardiac vascular disease. <i>Current Opinion in Cardiology</i> , 2012 , 27, 392-7	2.1	17
251	The fats of life in diabetes. <i>British Journal of Diabetes and Vascular Disease</i> , 2012 , 12, 216-220		3
250	Diagnosis and treatment of severe hypertriglyceridemia. <i>Expert Review of Cardiovascular Therapy</i> , 2012 , 10, 505-14	2.5	23
249	Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?. <i>European Journal of Preventive Cardiology</i> , 2012 , 19, 474-83	3.9	13
248	Nonalcoholic fatty liver disease and lipids. <i>Current Opinion in Lipidology</i> , 2012 , 23, 345-52	4.4	42
247	Association of bone turnover markers and arterial stiffness in pre-dialysis chronic kidney disease (CKD). <i>Bone</i> , 2011 , 48, 1127-32	4.7	33
246	Ideal lipid profile and genes for an extended life span. <i>Current Opinion in Cardiology</i> , 2011 , 26, 348-55	2.1	11
245	Pulmonary arterial hypertension and statins: an update. <i>Current Opinion in Cardiology</i> , 2011 , 26, 322-6	2.1	15
244	"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. <i>Current Vascular Pharmacology</i> , 2011 , 9, 531-2	3.3	91
243	Gender-based cardiometabolic risk evaluation in minority and non-minority men grading the evidence of non-traditional determinants of cardiovascular risk. <i>International Journal of Clinical Practice</i> , 2011 , 65, 134-47	2.9	7
242	Rimonabant improves cholesterol, insulin resistance and markers of non-alcoholic fatty liver in morbidly obese patients: a retrospective cohort study. <i>International Journal of Clinical Practice</i> , 2011 , 65, 713-5	2.9	8
241	A renaissance for cardio-metabolic surgery: better outcomes and lower costs?. <i>International Journal of Clinical Practice</i> , 2011 , 65, 728-32	2.9	3
240	The incidence of low eGFR and proteinuria in a large tertiary referral lipid clinic. <i>International Urology and Nephrology</i> , 2011 , 43, 821-5	2.3	1
239	The assessment of metabolic syndrome in UK patients with HIV using two different definitions: CREATE 2 study. <i>Current Medical Research and Opinion</i> , 2011 , 27, 63-9	2.5	14
238	New lipid modulating drugs: the role of microsomal transport protein inhibitors. <i>Current Pharmaceutical Design</i> , 2011 , 17, 943-9	3.3	24
237	"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. <i>Current Vascular Pharmacology</i> , 2011 , 9, 533-7	3.3	138
236	Investigating mixed hyperlipidaemia. <i>BMJ, The</i> , 2011 , 343, d5146	5.9	1

235	Putting protection first: vascular risk assessment in atypical populations. <i>International Journal of Clinical Practice</i> , 2010 , 64, 664-6	2.9	2
234	Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study. <i>International Journal of Clinical Practice</i> , 2010 , 64, 1252-9	2.9	41
233	Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia. <i>Drug, Healthcare and Patient Safety</i> , 2010 , 2, 61-71	1.6	4
232	The effectiveness of long-term dietary therapy in the treatment of adult Refsum disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010 , 81, 954-7	5.5	54
231	The effect of fibrate-statin combination therapy on cardiovascular events: a retrospective cohort analysis. <i>Current Medical Research and Opinion</i> , 2010 , 26, 2141-6	2.5	10
230	Hyperlipidaemia in paediatric patients: the role of lipid-lowering therapy in clinical practice. <i>Drug Safety</i> , 2010 , 33, 115-25	5.1	16
229	Adult Refsum disease: a form of tapetoretinal dystrophy accessible to therapy. <i>Survey of Ophthalmology</i> , 2010 , 55, 531-8	6.1	29
228	Sodium-glucose co-transporter 2 inhibitors: from apple tree to 'Sweet Pee'. <i>Current Pharmaceutical Design</i> , 2010 , 16, 3830-8	3.3	8
227	Aortic stenosis and lipids: does intervention work?. <i>Current Opinion in Cardiology</i> , 2010 , 25, 379-84	2.1	12
226	Fibrates: no ACCORD on their use in the treatment of dyslipidaemia. <i>Current Opinion in Lipidology</i> , 2010 , 21, 352-8	4.4	26
225	Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association?. <i>Current Opinion in Cardiology</i> , 2010 , 25, 406-10	2.1	21
224	Colesevelam: an improved bile acid sequestrant for treating hypercholesterolemia and improving diabetes. <i>Expert Review of Endocrinology and Metabolism</i> , 2010 , 5, 825-834	4.1	1
223	Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease. <i>Osteoporosis International</i> , 2010 , 21, 1853-61	5.3	68
222	Getting better value from the NHS drug budget. <i>BMJ, The</i> , 2010 , 341, c6449	5.9	15
221	The copper/caeruloplasmin ratio in routine clinical practice in different laboratories. <i>Journal of Clinical Pathology</i> , 2009 , 62, 60-3	3.9	11
220	Targeting triglycerides in secondary prevention: should we bother?. <i>International Journal of Clinical Practice</i> , 2009 , 63, 15-8	2.9	2
219	SEARCHing for JUPITER: starry-eyed optimism is not warranted. <i>International Journal of Clinical Practice</i> , 2009 , 63, 685-8	2.9	3
218	Truthiness and quality improvement. <i>International Journal of Clinical Practice</i> , 2009 , 63, 839-40	2.9	

217	Vascular risk screening: possible or too much, too soon?. <i>International Journal of Clinical Practice</i> , 2009 , 63, 989-96	2.9	5
216	Storms, tea cups and the adverse effects of statins. <i>International Journal of Clinical Practice</i> , 2009 , 63, 1268-70	2.9	3
215	Hot and bothered: C-reactive protein, inflammation and atherosclerosis. <i>International Journal of Clinical Practice</i> , 2009 , 63, 1550-3	2.9	4
214	Interpreting clinical trials of diabetic dyslipidaemia: new insights. <i>Diabetes, Obesity and Metabolism</i> , 2009 , 11, 261-70	6.7	6
213	Factors regulating circulating vascular endothelial growth factor (VEGF): association with bone mineral density (BMD) in post-menopausal osteoporosis. <i>Cytokine</i> , 2009 , 46, 376-81	4	26
212	Are intensive lipid-lowering regimens an optimal economic strategy in patients with ACS? An acute and chronic perspective. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2009 , 9, 423-33	2.2	2
211	Lipoprotein a: where are we now?. <i>Current Opinion in Cardiology</i> , 2009 , 24, 351-7	2.1	44
210	Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia. <i>Current Opinion in Cardiology</i> , 2009 , 24, 372-9	2.1	27
209	Future challenges for microsomal transport protein inhibitors. <i>Current Vascular Pharmacology</i> , 2009 , 7, 277-86	3.3	42
208	Potential options to treat hypertriglyceridaemia. <i>Current Drug Targets</i> , 2009 , 10, 356-62	3	6
207	The relationship between gonadotrophins, gonadal hormones and bone mass in men. <i>Clinical Endocrinology</i> , 2008 , 68, 94-101	3.4	13
206	Waist circumference, metabolic syndrome and coronary artery disease in a Pakistani cohort. <i>International Journal of Cardiology</i> , 2008 , 128, 77-82	3.2	7
205	Epidemiological studies are meaningless without proof of long-term data stability. <i>American Journal of Medicine</i> , 2008 , 121, e7; author reply e9-10	2.4	2
204	The 2007 Heart-UK Survey of Lipid Clinics and Clinical Practice in the UK. <i>Atherosclerosis</i> , 2008 , 199, 234	3.1	2
203	HIV lipodystrophy and its metabolic consequences: implications for clinical practice. <i>Current Medical Research and Opinion</i> , 2008 , 24, 609-24	2.5	33
202	Identifying patients with familial hypercholesterolaemia in primary care: an informatics-based approach in one primary care centre. <i>Heart</i> , 2008 , 94, 754-8	5.1	52
201	Colesevelam hydrochloride: a specifically engineered bile acid sequestrant. <i>Future Lipidology</i> , 2008 , 3, 237-255		13
200	Familial combined hyperlipidaemia: under - defined and under - diagnosed?. <i>Current Vascular Pharmacology</i> , 2008 , 6, 13-22	3.3	27

199	Review: Clinical aspects of the management of HIV lipodystrophy. <i>British Journal of Diabetes and Vascular Disease</i> , 2008 , 8, 113-119		3
198	Targeted versus global approaches to the management of hypercholesterolaemia. <i>Perspectives in Public Health</i> , 2008 , 128, 248-54		3
197	New approaches in the diagnosis of atherosclerosis and treatment of cardiovascular disease. <i>Recent Patents on Cardiovascular Drug Discovery</i> , 2008 , 3, 84-91		9
196	Detection of small dense LDL-cholesterol: is it necessary to determine particle size?. <i>Future Lipidology</i> , 2008 , 3, 23-25		1
195	The relationship between serum copper and ceruloplasmin in routine clinical practice. <i>International Journal of Clinical Practice</i> , 2008 , 62, 485-7	2.9	6
194	Non-ceruloplasmin-bound copper in routine clinical practice in different laboratories. <i>Journal of Trace Elements in Medicine and Biology</i> , 2008 , 22, 50-3	4.1	21
193	Multiple actions of high-density lipoprotein. <i>Current Opinion in Cardiology</i> , 2008 , 23, 370-8	2.1	154
192	Lipoproteins: from A to B and maybe C-III. <i>International Journal of Clinical Practice</i> , 2008 , 62, 674-6	2.9	5
191	Enhanced LDL-C reduction: lower is better. Does it matter how?. <i>International Journal of Clinical Practice</i> , 2008 , 62, 518-20	2.9	5
190	Insulin resistance phenotypes and coronary artery disease in a native Pakistani cohort. <i>International Journal of Clinical Practice</i> , 2008 , 62, 701-7	2.9	2
189	A fishy business: omega-3 fatty acids and cardiovascular disease. <i>International Journal of Clinical Practice</i> , 2008 , 62, 1142-6	2.9	14
188	Surrogate markers, atherosclerosis and cardiovascular disease prevention. <i>International Journal of Clinical Practice</i> , 2008 , 62, 981-7	2.9	23
187	Muddy waters: more stormy SEAS for ezetimibe. <i>International Journal of Clinical Practice</i> , 2008 , 62, 1470-3	2.9	11
186	Alpha-methylacyl-CoA racemase--an 'obscure' metabolic enzyme takes centre stage. <i>FEBS Journal</i> , 2008 , 275, 1089-102	5.7	82
185	Familial hypercholesterolaemia: summary of NICE guidance. <i>BMJ, The</i> , 2008 , 337, a1095	5.9	162
184	Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study. <i>Diabetes/Metabolism Research and Reviews</i> , 2007 , 23, 392-9	7.5	45
183	Percentage non-ceruloplasmin bound copper. <i>Clinical Biochemistry</i> , 2007 , 40, 749-50	3.5	9
182	Targets--who needs them? Success with statin therapies. <i>International Journal of Clinical Practice</i> , 2007 , 61, 1239-42	2.9	0

181	Primary and secondary prevention in obesity. <i>International Journal of Clinical Practice</i> , 2007 , 61, 1431-4	2.9	2
180	Intervening on HDL-C: is it possible? Does it work?. <i>International Journal of Clinical Practice</i> , 2007 , 61, 1782-6	2.9	2
179	Quality as well as quantity? Beyond low-density lipoprotein-cholesterol - the role of particle size. <i>International Journal of Clinical Practice</i> , 2007 , 61, 1780-2	2.9	8
178	Lipid-altering therapies and the progression of atherosclerotic disease. <i>CardioVascular and Interventional Radiology</i> , 2007 , 30, 155-60	2.7	5
177	Copper:caeruloplasmin ratio. <i>Journal of Clinical Pathology</i> , 2007 , 60, 441-2	3.9	22
176	Homocysteine and cardiovascular disease: a review of the evidence. <i>Diabetes and Vascular Disease Research</i> , 2007 , 4, 143-50	3.3	202
175	Asymmetric dimethylarginine and reduced nitric oxide bioavailability in young Black African men. <i>Hypertension</i> , 2007 , 49, 873-7	8.5	59
174	Dr Brian Gibberd (1931-2006): a pioneering clinician in Refsum's disease. <i>Biochemical Society Transactions</i> , 2007 , 35, 862-4	5.1	
173	Peroxisomal disorders affecting phytanic acid alpha-oxidation: a review. <i>Biochemical Society Transactions</i> , 2007 , 35, 881-6	5.1	51
172	Lipid-Altering Therapies and the Progression of Atherosclerotic Disease. <i>CardioVascular and Interventional Radiology</i> , 2007 , 30, 155	2.7	
171	Limitations of non-ceruloplasmin-bound copper in routine clinical practice. <i>Gut</i> , 2007 , 56, 154	19.2	14
170	Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolaemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing. <i>Journal of Molecular Medicine</i> , 2006 , 84, 203-14	5.5	55
169	Plasma lipid profiles of women with intrahepatic cholestasis of pregnancy. <i>Obstetrics and Gynecology</i> , 2006 , 107, 106-14	4.9	46
168	Low-density lipoprotein apolipoprotein B100 turnover in hypopituitary patients with GH deficiency: a stable isotope study. <i>European Journal of Endocrinology</i> , 2006 , 154, 459-66	6.5	8
167	Adjusting copper concentrations for caeruloplasmin levels in routine clinical practice. <i>Journal of Clinical Pathology</i> , 2006 , 59, 867-9	3.9	14
166	Spinning stars: ASTEROID's impact on atherosclerosis. <i>Lancet, The</i> , 2006 , 367, 1655-6	4.0	1
165	Asymmetric dimethyl arginine levels correlate with cardiovascular risk factors in patients with erectile dysfunction. <i>Atherosclerosis</i> , 2006 , 185, 421-5	3.1	28
164	Fibrates after the FIELD study: Some answers, more questions. <i>Diabetes and Vascular Disease Research</i> , 2006 , 3, 166-71	3.3	10

163	Cardiovascular risk factors determine erectile and arterial function response to sildenafil. <i>American Journal of Hypertension</i> , 2006 , 19, 915-9	2.3	19
162	Future approaches to reducing low-density lipoprotein cholesterol. <i>Future Lipidology</i> , 2006 , 1, 463-476		1
161	Diabetic dyslipidaemia: the triad. <i>Country Review Ukraine</i> , 2006 , 8, F30-F33		1
160	FIELDS of dreams, fields of tears: a perspective on the fibrate trials. <i>International Journal of Clinical Practice</i> , 2006 , 60, 442-9	2.9	44
159	Erectile dysfunction and statin treatment in high cardiovascular risk patients. <i>International Journal of Clinical Practice</i> , 2006 , 60, 141-5	2.9	56
158	Lipid lowering, statins and cancer. <i>International Journal of Clinical Practice</i> , 2006 , 60, 1022-4	2.9	2
157	Rimonabant: endocannabinoid inhibition for the metabolic syndrome. <i>International Journal of Clinical Practice</i> , 2006 , 60, 1697-706	2.9	28
156	Statins and hypertension. <i>Journal of Human Hypertension</i> , 2006 , 20, 554-6	2.6	8
155	Cardiovascular risk assessment. <i>Lancet, The</i> , 2005 , 365, 1305-6	4.0	2
154	Dyslipidaemia and cardiovascular risk in HIV infection. <i>Current Medical Research and Opinion</i> , 2005 , 21, 1717-25	2.5	17
153	Impaired renal function and atherosclerosis in a Pakistani cohort. <i>Current Medical Research and Opinion</i> , 2005 , 21, 1201-7	2.5	3
152	The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel. <i>Current Medical Research and Opinion</i> , 2005 , 21, 959-69	2.5	62
151	A review of the lipid-related effects of fluvastatin. <i>Current Medical Research and Opinion</i> , 2005 , 21, 231-4	2.5	34
150	Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention?. <i>Current Medical Research and Opinion</i> , 2005 , 21, 299-306	2.5	18
149	Molecular mechanisms of atherosclerosis. <i>International Journal of Clinical Practice</i> , 2005 , 59, 1120-1120	2.9	
148	Ezetimibe-induced hyperlipidaemia. <i>International Journal of Clinical Practice</i> , 2005 , 59, 3-5	2.9	9
147	Hypertriglyceridaemia and malignancy. <i>International Journal of Clinical Practice</i> , 2005 , 59, 253-5	2.9	3
146	Molecular genetics and phenotypic characteristics of MODY caused by hepatocyte nuclear factor 4alpha mutations in a large European collection. <i>Diabetologia</i> , 2005 , 48, 878-85	10.3	170

145	The role of dyslipidaemia in coronary heart disease. <i>British Journal of Diabetes and Vascular Disease</i> , 2005 , 5, S2-S6		
144	Metabolic syndrome and risk of coronary heart disease in a Pakistani cohort. <i>Heart</i> , 2005 , 91, 1003-7	5.1	17
143	Letter regarding article by Gazzaruso et al, "Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated, type 2 diabetic patients". <i>Circulation</i> , 2005 , 111, e18-9; author reply e18-9	16.7	1
142	Very low plasma copper levels do not automatically imply severe copper deficiency. <i>Annals of Clinical Biochemistry</i> , 2005 , 42, 405; author reply 405-6	2.2	5
141	Images in clinical medicine. Lipemia retinalis. <i>New England Journal of Medicine</i> , 2005 , 353, 823	59.2	8
140	Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias. <i>Current Medical Research and Opinion</i> , 2005 , 21, 333-8	2.5	36
139	Relationship between serum copper, ceruloplasmin, and non-ceruloplasmin-bound copper in routine clinical practice. <i>Clinical Chemistry</i> , 2005 , 51, 1558-9	5.5	87
138	Effects of growth hormone (GH) replacement therapy on low-density lipoprotein apolipoprotein B100 kinetics in adult patients with GH deficiency: a stable isotope study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 1801-7	5.6	19
137	Polymorphisms in the P450 c17 (17-hydroxylase/17,20-Lyase) and P450 c19 (aromatase) genes: association with serum sex steroid concentrations and bone mineral density in postmenopausal women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 344-51	5.6	99
136	Does activity in research correlate with visibility?. <i>Journal of Clinical Pathology</i> , 2004 , 57, 426-7	3.9	5
135	Screening for cardiovascular disease. <i>European Heart Journal</i> , 2004 , 25, 996; author reply 996-7	9.5	1
134	Smell testing: an additional tool for identification of adult Refsum's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2004 , 75, 1334-6	5.5	19
133	The casino of life. <i>Journal of Clinical Pathology</i> , 2004 , 57, 243-4	3.9	1
132	Chemical pathology and the new contract for GPs. <i>Journal of Clinical Pathology</i> , 2004 , 57, 1022-4	3.9	7
131	Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes. <i>Diabetes Care</i> , 2004 , 27, 2569-70	14.6	47
130	Waist-hip ratio and low HDL predict the risk of coronary artery disease in Pakistanis. <i>Current Medical Research and Opinion</i> , 2004 , 20, 55-62	2.5	35
129	Effect of moxonidine on lipid subfractions in patients with hypertension. <i>International Journal of Clinical Practice</i> , 2004 , 58, 465-8	2.9	17
128	Cardiovascular disease in renal allograft recipients is associated with elevated sialic acid or markers of inflammation. <i>Clinical Transplantation</i> , 2004 , 18, 201-4	3.8	22

127	Lipid-altering agents: the future. <i>International Journal of Clinical Practice</i> , 2004 , 58, 1063-72	2.9	14
126	Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: a randomized controlled trial. <i>American Journal of Medical Genetics Part A</i> , 2004 , 128A, 285-93		148
125	Lipid-lowering therapies in development. <i>Expert Opinion on Investigational Drugs</i> , 2004 , 13, 1405-18	5.9	5
124	Concordance evaluation of coronary risk scores: implications for cardiovascular risk screening. <i>Current Medical Research and Opinion</i> , 2004 , 20, 811-8	2.5	22
123	Clinical significance of oxidation from phytol to phytanic acid in man. <i>Molecular Genetics and Metabolism</i> , 2004 , 83, 347	3.7	5
122	Cost utility of prenatal diagnosis. <i>Lancet, The</i> , 2004 , 363, 1165	4.0	
121	Cardiovascular risk factors and endothelial dysfunction. <i>Clinical Science</i> , 2004 , 107, 609-15	6.5	27
120	Accuracy of cardiovascular risk estimation. <i>Clinical Chemistry</i> , 2003 , 49, 706-7	5.5	
119	Ezetimibe. <i>American Journal of Cardiovascular Drugs</i> , 2003 , 3, 77-78	4	1
118	Accuracy of Cardiovascular Risk Estimation in Patients without Diabetes. <i>Clinical Science</i> , 2003 , 104, 16P-16P		
117	Statin therapy in people with diabetes and high-risk patients. <i>British Journal of Hospital Medicine</i> , 2003 , 64, 16-9		2
116	Relation of erectile dysfunction to angiographic coronary artery disease. <i>American Journal of Cardiology</i> , 2003 , 91, 230-1	3	186
115	The lipid and non-lipid effects of statins 2003 , 99, 95-112		200
114	Statin-fibrate combination: therapy for hyperlipidemia: a review. <i>Current Medical Research and Opinion</i> , 2003 , 19, 155-68	2.5	139
113	More on PROSPER. <i>Lancet, The</i> , 2003 , 361, 1135-6; author reply 1136	4.0	10
112	The chemical biology of branched-chain lipid metabolism. <i>Progress in Lipid Research</i> , 2003 , 42, 359-76	14.3	64
111	Imidazole derivatives as cholesterol-lowering agents. <i>International Journal of Cardiology</i> , 2003 , 90, 145-146		3
110	Cerivastatin monotherapy-induced muscle weakness, rhabdomyolysis and acute renal failure. <i>International Journal of Cardiology</i> , 2003 , 91, 107-9	3.2	5

109	Identification of PEX7 as the second gene involved in Refsum disease. <i>American Journal of Human Genetics</i> , 2003 , 72, 471-7	11	127
108	Ezetimibe: profile report. <i>Drugs and Therapy Perspectives</i> , 2003 , 19, 5-7	1.5	
107	Issues to consider when attempting to achieve the American Diabetes Association clinical quality requirement for haemoglobin A1c. <i>Current Medical Research and Opinion</i> , 2003 , 19, 719-23	2.5	22
106	Metabolism of phytanic acid and 3-methyl-adipic acid excretion in patients with adult Refsum disease. <i>Journal of Lipid Research</i> , 2003 , 44, 1481-8	6.3	28
105	New lipid-lowering agents. <i>Expert Opinion on Emerging Drugs</i> , 2003 , 8, 365-76	3.7	10
104	Simple sequence-specific-primer-PCR method to identify the three main apolipoprotein E haplotypes. <i>Clinical Chemistry</i> , 2003 , 49, 1945-8	5.5	26
103	Role of phytanoyl-CoA 2-hydroxylase in phytanic acid metabolism. <i>Advances in Experimental Medicine and Biology</i> , 2003 , 544, 303-4	3.6	1
102	Identification of PEX7 as the second gene involved in Refsum disease. <i>Advances in Experimental Medicine and Biology</i> , 2003 , 544, 69-70	3.6	11
101	Erectile dysfunction: cardiovascular risk and the role of the cardiologist. <i>International Journal of Clinical Practice</i> , 2003 , 57, 96-9	2.9	38
100	Raised plasma total sialic acid levels are markers of cardiovascular disease in renal dialysis patients. <i>Journal of Nephrology</i> , 2003 , 16, 540-5	4.8	17
99	Hypertriglyceridaemia and NK cell lymphoma. <i>International Journal of Clinical Practice</i> , 2003 , 57, 921-2	2.9	2
98	Effect of IGF-I therapy on VLDL apolipoprotein B100 metabolism in type 1 diabetes mellitus. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2002 , 282, E1154-62	6	8
97	Usefulness of Orlistat in the treatment of severe hypertriglyceridemia. <i>American Journal of Cardiology</i> , 2002 , 89, 229-31	3	24
96	Refsum's disease: a peroxisomal disorder affecting phytanic acid alpha-oxidation. <i>Journal of Neurochemistry</i> , 2002 , 80, 727-35	6	147
95	Utilization of sterol carrier protein-2 by phytanoyl-CoA 2-hydroxylase in the peroxisomal alpha oxidation of phytanic acid. <i>Chemistry and Biology</i> , 2002 , 9, 597-605		44
94	Lipid lowering: another method of reducing blood pressure?. <i>Journal of Human Hypertension</i> , 2002 , 16, 753-60	2.6	33
93	The uptake of lipoprotein-borne phylloquinone (vitamin K1) by osteoblasts and osteoblast-like cells: role of heparan sulfate proteoglycans and apolipoprotein E. <i>Journal of Bone and Mineral Research</i> , 2002 , 17, 426-33	6.3	46
92	Accuracy of cardiovascular risk estimation for primary prevention in patients without diabetes. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2002 , 9, 183-90		25

91	. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2002 , 9, 183-190		57
90	Beyond LDL-C--the importance of raising HDL-C. <i>Current Medical Research and Opinion</i> , 2002 , 18, 36-44	2.5	33
89	Stroke in systemic lupus erythematosus. <i>Expert Review of Neurotherapeutics</i> , 2002 , 2, 385-90	4.3	
88	The apolipoprotein E2 allele modulates activity and maximal velocity of the sodium-lithium countertransporter. <i>American Journal of Hypertension</i> , 2002 , 15, 633-7	2.3	6
87	Dose-response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies. <i>International Journal of Cardiology</i> , 2002 , 84, 53-7	3.2	41
86	Total research productivity in a pathology discipline. <i>Journal of Clinical Pathology</i> , 2002 , 55, 495-8	3.9	8
85	Normal VLDL metabolism despite altered lipoprotein composition in type 1 diabetes mellitus. <i>Clinical Endocrinology</i> , 2001 , 55, 777-87	3.4	11
84	Vascular and blood pressure effects of folic acid in older patients with cardiovascular disease. <i>Journal of the American Geriatrics Society</i> , 2001 , 49, 1003-4	5.6	14
83	Studies on phytanoyl-CoA 2-hydroxylase and synthesis of phytanoyl-coenzyme A. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2001 , 11, 2545-8	2.9	21
82	Very low-density lipoprotein apolipoprotein B-100 turnover in glycogen storage disease type Ia (von Gierke disease). <i>Journal of Inherited Metabolic Disease</i> , 2001 , 24, 527-34	5.4	6
81	Erythrocyte sodium-lithium countertransport in African American women. <i>Journal of Human Hypertension</i> , 2001 , 15, 505-6	2.6	1
80	Fibrinogen response with simvastatin versus atorvastatin in familial hypercholesterolemia. <i>American Journal of Cardiology</i> , 2001 , 87, 338-40, A9	3	9
79	Time to look beyond just lowering the serum concentration of low density lipoprotein--high density lipoprotein levels are also important. <i>Perspectives in Public Health</i> , 2001 , 121, 98-101		1
78	Atorvastatin for acute coronary syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2001 , 286, 532-3; author reply 533-5	27.4	1
77	Structure-function analysis of phytanoyl-CoA 2-hydroxylase mutations causing Refsum's disease. <i>Human Molecular Genetics</i> , 2001 , 10, 1971-82	5.6	58
76	Is a mechanical or a metabolic approach superior in the treatment of coronary disease? Results of the atorvastatin versus revascularization (AVERT) trial. <i>European Heart Journal</i> , 2001 , 22, 972-3	9.5	4
75	Lipid-lowering drugs in lupus: an unexplored therapeutic intervention. <i>Lupus</i> , 2001 , 10, 233-6	2.6	2
74	Relation between sodium-lithium countertransport and hypertriglyceridemia in type V hyperlipidemia. <i>American Journal of Hypertension</i> , 2001 , 14, 32-7	2.3	6

73	Statins and fractures. <i>Lancet, The</i> , 2001 , 357, 1887-9	40	3
72	Measurement of atherosclerosis progression. <i>Lancet, The</i> , 2001 , 358, 329-30	40	0
71	Drug treatment of combined hyperlipidemia. <i>American Journal of Cardiovascular Drugs</i> , 2001 , 1, 327-36	4	18
70	Atorvastatin. <i>Expert Opinion on Pharmacotherapy</i> , 2001 , 2, 819-30	4	19
69	Chemical co-substrate rescue of phytanoyl-CoA 2-hydroxylase mutants causing Refsum Disease. <i>Chemical Communications</i> , 2001 , 972-973	5.8	21
68	Synthetic Statins: More Data on Newer Lipid-lowering Agents. <i>Current Medical Research and Opinion</i> , 2001 , 17, 74-77	2.5	8
67	Comparison of therapy with simvastatin 80 mg and 120 mg in patients with familial hypercholesterolaemia. <i>International Journal of Clinical Practice</i> , 2001 , 55, 673-5	2.9	5
66	A comparison of algorithms for initiation of lipid lowering therapy in primary prevention of coronary heart disease. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2000 , 7, 63-71		16
65	Differing relationships of methylene tetrahydrofolate reductase genotypes with cardiovascular risk in familial and polygenic hypercholesterolaemia. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2000 , 7, 431-4		
64	Attaining United States and European Guideline LDL-C Levels with Simvastatin in Patients with Coronary Heart Disease (the GOALLS Study). <i>Current Medical Research and Opinion</i> , 2000 , 16, 205-207	2.5	2
63	Identification of genetic heterogeneity in Refsum's disease. <i>European Journal of Human Genetics</i> , 2000 , 8, 649-51	5.3	33
62	A randomised placebo controlled trial of the effects of tibolone on blood pressure and lipids in hypertensive women. <i>Journal of Human Hypertension</i> , 2000 , 14, 99-104	2.6	33
61	Effects of lipids in patients with familial hypercholesterolaemia on the kinetics of the sodium-lithium countertransporter. <i>Journal of Human Hypertension</i> , 2000 , 14, 561-5	2.6	1
60	High-density lipoprotein cholesterol and triglyceride response with simvastatin versus atorvastatin in familial hypercholesterolemia. <i>American Journal of Cardiology</i> , 2000 , 86, 547-9, A9	3	19
59	Classification of acute MI. <i>European Heart Journal</i> , 2000 , 21, 857-8	9.5	
58	HDL-cholesterol and the Treatment of Coronary Heart Disease: Contrasting Effects of Atorvastatin and Simvastatin. <i>Current Medical Research and Opinion</i> , 2000 , 16, 139-146	2.5	48
57	Natural statins and stroke. <i>Circulation</i> , 2000 , 101, E45	16.7	1
56	Renin-angiotensin system polymorphisms and coronary events in familial hypercholesterolemia. <i>Hypertension</i> , 2000 , 36, 808-12	8.5	28

55	Are drugs interchangeable?. <i>Lancet, The</i> , 2000 , 355, 317; author reply 317-8	40	2
54	Effects of statins. <i>Lancet, The</i> , 2000 , 356, 1195	40	3
53	Coronary heart disease in Indian Asians. <i>Lancet, The</i> , 2000 , 355, 1727-8	40	1
52	Lipids, cardiovascular disease and atherosclerosis in systemic lupus erythematosus. <i>Lupus</i> , 2000 , 9, 194-204	31	31
51	More on the effect of atorvastatin on plasma fibrinogen levels in primary hypercholesterolaemia. <i>Atherosclerosis</i> , 2000 , 148, 204	3.1	14
50	Serum homocysteine, folate and thermolabile variant of MTHFR in healthy Sri Lankans living in London. <i>Atherosclerosis</i> , 2000 , 149, 221-2	3.1	3
49	National service framework's financial implications are huge. <i>BMJ: British Medical Journal</i> , 2000 , 321, 705		
48	Cost effectiveness of statins. <i>British Heart Journal</i> , 2000 , 83, 713-4		
47	HDL-cholesterol and the treatment of coronary heart disease: contrasting effects of atorvastatin and simvastatin. <i>Current Medical Research and Opinion</i> , 2000 , 16, 139-46	2.5	4
46	Effects of growth hormone (GH) replacement therapy on very low density lipoprotein apolipoprotein B100 kinetics in patients with adult GH deficiency: a stable isotope study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 307-16	5.6	38
45	Urinary retinol-binding protein (RBP) excretion and erythrocyte sodium-lithium countertransport (SLC) activity in a cohort of healthy normotensive subjects. <i>Journal of Human Hypertension</i> , 1999 , 13, 871-3	2.6	
44	Transport of phytanic acid on lipoproteins in Refsum disease. <i>Journal of Inherited Metabolic Disease</i> , 1999 , 22, 29-36	5.4	13
43	Cholestatic liver dysfunction. <i>Lancet, The</i> , 1999 , 354, 954	40	9
42	Thrombotic vascular events after change of statin. <i>Lancet, The</i> , 1999 , 353, 845	40	7
41	Atorvastatin compared with simvastatin-based therapies in the management of severe familial hyperlipidaemias. <i>QJM - Monthly Journal of the Association of Physicians</i> , 1999 , 92, 387-94	2.7	40
40	The role of lipid lowering in transplantation. <i>International Journal of Clinical Practice</i> , 1999 , 53, 54-9	2.9	11
39	Comparison of therapy with simvastatin 80 mg and atorvastatin 80 mg in patients with familial hypercholesterolaemia. <i>International Journal of Clinical Practice</i> , 1999 , 53, 609-11	2.9	30
38	Influence of plasma phytanic acid levels in Refsum's disease on the behaviour of the erythrocyte membrane sodium-lithium countertransporter. <i>European Journal of Clinical Investigation</i> , 1998 , 28, 334-8	4.6	1

37	Effect of atorvastatin on plasma fibrinogen. <i>Lancet, The</i> , 1998 , 351, 569-70	40	81
36	Statins and fibrinogen. <i>Lancet, The</i> , 1998 , 351, 1431-1432	40	2
35	Lipid lowering therapy in patients with HIV infection. <i>Lancet, The</i> , 1998 , 352, 1782	40	15
34	Laboratory investigations by DNA amplification: from research to practice. <i>Annals of Clinical Biochemistry</i> , 1998 , 35 (Pt 1), 5-11	2.2	3
33	High-dose atorvastatin therapy in severe heterozygous familial hypercholesterolaemia. <i>QJM - Monthly Journal of the Association of Physicians</i> , 1998 , 91, 291-4	2.7	15
32	People at risk of coronary heart disease should not be denied treatment with effective drugs for purely financial reasons. <i>BMJ: British Medical Journal</i> , 1998 , 317, 80		
31	Profound hyponatraemia following an idiosyncratic reaction to diuretics. <i>International Journal of Clinical Practice</i> , 1998 , 52, 278-9	2.9	3
30	Fenofibrate plus simvastatin therapy versus simvastatin plus cholestyramine therapy for familial hypercholesterolaemia. <i>QJM - Monthly Journal of the Association of Physicians</i> , 1997 , 90, 631-4	2.7	19
29	Hyperlipidaemia in association with benign paraproteinaemia. <i>Annals of Clinical Biochemistry</i> , 1997 , 34 (Pt 6), 697-9	2.2	3
28	Preserved endothelial function in patients with severe hypertriglyceridemia and low functional lipoprotein lipase activity. <i>Journal of the American College of Cardiology</i> , 1997 , 29, 964-8	15.1	73
27	Diagnosis and management of hyperlipidaemia. <i>International Journal of Clinical Practice</i> , 1997 , 51, 378-83.	9	1
26	Sheffield risk and treatment table for primary prevention of coronary heart disease. <i>Lancet, The</i> , 1996 , 348, 1039-40; author reply 1040-1	40	3
25	Familial hyperchylomicronaemia. <i>Lancet, The</i> , 1996 , 348, 1524-5	40	10
24	Patients with recurrent renal stones have a physico-chemically altered urinary Tamm-Horsfall glycoprotein profile. <i>Annals of Clinical Biochemistry</i> , 1996 , 33 (Pt 6), 540-4	2.2	5
23	Cost effectiveness of lowering cholesterol. Full treatment of the costs and benefits is needed. <i>BMJ: British Medical Journal</i> , 1996 , 313, 1143; author reply 1144		
22	Association of angiotensin converting enzyme DD genotype with hypertension in diabetes. <i>Journal of Human Hypertension</i> , 1995 , 9, 671-3	2.6	9
21	Health promotion in general practice. Any beneficial effect was lost in background statistical noise. <i>BMJ: British Medical Journal</i> , 1995 , 310, 532-3		1
20	Strategies for reducing coronary risk factors in primary care. <i>BMJ: British Medical Journal</i> , 1995 , 311, 263		

19	Maternal serum free beta hCG screening: results of studies including 480 cases of Down syndrome--problems with this approach. <i>Prenatal Diagnosis</i> , 1994 , 14, 1093; author reply 1094-5	3.2	1
18	Glycated haemoglobin values. Methodological discrepancies are not important. <i>BMJ: British Medical Journal</i> , 1994 , 309, 1511		
17	Copper-64 metabolism in two patients with non-Wilsonian movement disorders and copper deficiency. <i>Journal of the Neurological Sciences</i> , 1993 , 119, 85-90	3.2	4
16	The tissue distribution of alpha 2-delta subunit genes of the voltage-gated calcium channel in rodent tissues and NG108-15 cells. <i>Annals of the New York Academy of Sciences</i> , 1993 , 681, 422-4	6.5	1
15	Tissue-specific expression of putative domains of the mouse neuronal alpha-2 and delta genes of the voltage-gated calcium channel in rodent tissues. <i>Annals of the New York Academy of Sciences</i> , 1993 , 707, 472-5	6.5	
14	Hairy leukaemic cell influx into the cerebrospinal fluid secondary to encephalomyelitis. <i>Postgraduate Medical Journal</i> , 1993 , 69, 651-3	2	0
13	Molecular biology techniques. <i>Annals of Clinical Biochemistry</i> , 1993 , 30 (Pt 3), 332-4	2.2	
12	Paget's disease of bone. <i>BMJ: British Medical Journal</i> , 1993 , 306, 333		
11	The hematological and electrophysiological effects of cobalamin. Deficiency secondary to vegetarian diets. <i>Annals of the New York Academy of Sciences</i> , 1992 , 669, 345-8	6.5	5
10	Cerebral neoplastic angioendotheliosis complicated by hypercalcaemia. <i>Postgraduate Medical Journal</i> , 1991 , 67, 571-3	2	
9	Immunocytological diagnosis of primary cerebral non-Hodgkin's lymphoma. <i>Journal of Clinical Pathology</i> , 1991 , 44, 251-3	3.9	10
8	Effect of haemolysate preparation on measurement of red cell folate by a radioisotopic method. <i>Journal of Clinical Pathology</i> , 1990 , 43, 160-2	3.9	9
7	Autoimmunity: a risk factor for allosensitization to blood products?. <i>BMJ: British Medical Journal</i> , 1989 , 298, 963		
6	Transient nephrotic syndrome after anaesthesia resulting from a familial cryofibrinogen precipitating at 35 degrees C. <i>Journal of Medical Genetics</i> , 1989 , 26, 631-6	5.8	8
5	Autoimmunity: a risk factor for allosensitisation to blood products?. <i>BMJ: British Medical Journal</i> , 1989 , 298, 95-6		
4	Screening for inherited metabolic diseases in adults with neurological disease. <i>Lancet, The</i> , 1988 , 1, 1101-4		
3	Lipid-Lowering in the Elderly Patient101-110		
2	Lipid Management68-89		

1 Cardiovascular Risk Factors 657-683

1